Results 31 to 40 of about 496,043 (271)

The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease☆

open access: yesCurrent opinion in pharmacology (Print), 2014
Highlights • Muscarinic receptors increase smooth muscle tone in airways and urinary bladder.• β-Adrenoceptors relax smooth muscle tone and oppose muscarinic contraction.• Opposition involves transmitter release, signal transduction and receptor ...
Philippa Dale   +6 more
semanticscholar   +1 more source

Time Course of the Increase in the Myocardial Slow Inward Current after a Photochemically Generated Concentration Jump of Intracellular cAMP [PDF]

open access: yes, 1983
Voltage-clamped atrial trabeculae from bullfrog hearts were exposed to membrane-permeant photolyzable o-nitrobenzyl esters of cAMP and cGMP. UV flashes produced intracellular concentration jumps of cAMP or cGMP. With the cAMP derivative, flashes resulted
Engels, Joachim   +3 more
core   +1 more source

M3 muscarinic acetylcholine receptor facilitates the endocytosis of mu opioid receptor mediated by morphine independently of the formation of heteromeric complexes [PDF]

open access: yes, 2017
Morphine inefficiency to induce the internalization of mu opioid (MOP) receptors observed in numerous experimental models constitutes a paradigm of G-protein coupled receptor (GPCR) functional selectivity.
Alvarez-Curto, Elisa   +2 more
core   +1 more source

Interaction of the Xanthine Nucleotide Binding Goα Mutant with G Protein-coupled Receptors [PDF]

open access: yes, 1998
We constructed a double mutant version of the α subunit of Go that was regulated by xanthine nucleotides instead of guanine nucleotides (GoαX). We investigated the interaction between GoαX and G protein-coupled receptors in vitro.
Simon, Melvin I., Yu, Bo
core   +1 more source

Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety

open access: yesTherapeutic Advances in Respiratory Disease, 2015
The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting ...
Erminia Ridolo   +4 more
doaj   +1 more source

Anticholinergic therapy for acute asthma in children. [PDF]

open access: yes, 2012
Inhaled anticholinergics as single agent bronchodilators (or in combination with beta(2)-agonists) are one of the several medications available for the treatment of acute asthma in ...
Beakes   +49 more
core   +2 more sources

Muscarinic modulation of M and h currents in gerbil spherical bushy cells.

open access: yesPLoS ONE, 2020
Descending cholinergic fibers innervate the cochlear nucleus. Spherical bushy cells, principal neurons of the anterior part of the ventral cochlear nucleus, are depolarized by cholinergic agonists on two different time scales.
Charlène Gillet   +2 more
doaj   +1 more source

RGS4 regulates partial agonism of the M2 muscarinic receptor-activated K+ currents. [PDF]

open access: yes, 2014
Partial agonists are used clinically to avoid overstimulation of receptor-mediated signalling, as they produce a submaximal response even at 100% receptor occupancy.
Chen, I-Shan   +3 more
core   +2 more sources

Radioprotective effect of lidocaine on neurotransmitter agonist-induced secretion in irradiated salivary glands. [PDF]

open access: yes, 2013
Previously we verified the radioprotective effect of lidocaine on the function and ultrastructure of salivary glands in rabbits. However, the underlying mechanism of lidocaine's radioprotective effect is unknown.
Benedek, Geza A.   +8 more
core   +3 more sources

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD : a systematic review and meta-analysis [PDF]

open access: yes, 2017
Acknowledgments The meta-analysis work was performed by Guruprasad Rao KS and Sharanbasappa Durg of Molecular Connections (P) Ltd, Bangalore, India, under the guidance of the manuscript authors and Novartis Pharma AG (Basel, Switzerland). Medical writing
Altman, Pablo   +8 more
core   +2 more sources

Home - About - Disclaimer - Privacy